After-Hours Stock Movers 12/06: (SEAC) (DPW) (TLRD) (LULU) Higher; (EGLT) (VRNT) (OLLI) Lower (more...)

December 6, 2017 6:06 PM

Today's After-Hours Movers

SeaChange Int'l (NASDAQ: SEAC) 21.4% HIGHER; reported Q3 EPS of $0.09, $0.08 better than the analyst estimate of $0.01. Revenue for the quarter came in at $23.4 million versus the consensus estimate of $19.51 million. GUIDANCE: SeaChange Int'l sees Q4 2018 EPS of $0.02-$0.10, versus the consensus of $0.06. SeaChange Int'l sees Q4 2018 revenue of $20-24 million, versus the consensus of $22.9 million.

Digital Power Corporation (NYSE: DPW) 17.2% HIGHER; stated today that it has entered into no agreement and has received no order from Amazon (NASDAQ: AMZN). DPW further avers it is not negotiating anything with Amazon

Tailored Brands (NYSE: TLRD) 14.2% HIGHER; reported Q3 EPS of $0.58, $0.04 better than the analyst estimate of $0.54. Revenue for the quarter came in at $810.82 million versus the consensus estimate of $807.5 million. Tailored Brands sees FY2017 EPS of $2.03-$2.08, versus the consensus of $1.84.

Egalet (NASDAQ: EGLT) 8.7% LOWER; has been notified verbally by CVS Caremark, a pharmacy benefits manager, that SPRIX Nasal Spray will no longer be on its formulary for a portion of its commercial covered lives beginning January 1, 2018. The Company estimates that approximately 20% of SPRIX prescriptions could be impacted by Caremark’s planned action.

lululemon athletica (NASDAQ: LULU) 6.3% HIGHER; reported Q3 EPS of $0.56, $0.04 better than the analyst estimate of $0.52. Revenue for the quarter came in at $619 million versus the consensus estimate of $609.9 million. Total comparable sales increased 8%, or increased 7% on a constant dollar basis. GUIDANCE: lululemon athletica sees Q4 2017 EPS of $1.19-$1.22 vs $1.17 consensus. lululemon athletica sees Q4 2017 revenue of $870-885 million vs $866.24 consensus. Also, announced that its board of directors has approved a new stock repurchase program for up to $200 million of its common shares in the open market.

Verint Systems (NASDAQ: VRNT) 6% LOWER; reported Q3 EPS of $0.66, $0.08 better than the analyst estimate of $0.58. Revenue for the quarter came in at $283.8 million versus the consensus estimate of $282.34 million.

Greif (NYSE: GEF) 3.9% HIGHER; reported Q4 EPS of $0.98, $0.09 better than the analyst estimate of $0.89. Revenue for the quarter came in at $968.1 million versus the consensus estimate of $933.25 million. Company Outlook Highlights of fiscal 2018 guidance are set forth below $3.25 - $3.55

Broadcom (NASDAQ: AVGO) 3.8% HIGHER; reported Q4 EPS of $4.59, $0.07 better than the analyst estimate of $4.52. Revenue for the quarter came in at $4.84 billion versus the consensus estimate of $4.83 billion. Sees Q1 revenues of $5.23-$5.38 billion, versus the consensus of $4.82 billion.

Okta, Inc. (NASDAQ: OKTA) 3.7% HIGHER; reported Q3 EPS of ($0.19), $0.05 better than the analyst estimate of ($0.24). Revenue for the quarter came in at $68.2 million versus the consensus estimate of $62.84 million. GUIDANCE: Okta, Inc. sees Q4 2018 EPS of ($0.18)-($0.17). Okta, Inc. sees Q4 2018 revenue of $70-71 million. Okta, Inc. sees Q4 2018 EPS of ($0.87)-($0.86). Okta, Inc. sees Q4 2018 revenue of $252-253 million.

Ollie's Bargain Outlet (NASDAQ: OLLI) 3.4% LOWER; reported Q3 EPS of $0.22, $0.01 better than the analyst estimate of $0.21. Revenue for the quarter came in at $238.1 million versus the consensus estimate of $233.74 million. Comparable store sales increased 2.1%. GUIDANCE: Ollie's Bargain Outlet sees FY2017 EPS of $1.21-$1.22, versus the consensus of $1.19. Ollie's Bargain Outlet sees FY2017 revenue of $1.062-1.065 billion, versus the consensus of $1.07 billion.

Spark Therapeutics (NASDAQ: ONCE) 3.3% HIGHER; Spark and Pfizer Inc. (NYSE: PFE), today announced that The New England Journal of Medicine has published interim data as of July 25, 2017, from the Phase 1/2 clinical trial of SPK-9001, an investigational gene therapy for hemophilia B. With a cumulative follow-up of 492 weeks observation of the first 10 adult male participants, the mean steady-state factor IX activity was 34 percent of normal (range of 14-81 percent) following a single administration of investigational SPK-9001. The annualized bleeding rate (ABR) was reduced 97 percent, from a mean rate of 11.1 events per year before vector administration to 0.4 events per year after vector administration (p=0.02), while factor IX concentrate use was reduced 99 percent (p=0.004).

Ctrip.com (NASDAQ: CTRP) 1.2% LOWER; JPMorgan downgraded from Overweight to Neutral with a price target of $45.00 (from $50.00).

Categories

Special Reports

Next Articles